Eric Velazquez

Jan 2, 2024 | jacc.org | David A. Morrow |Eric Velazquez |Akshay S. Desai |Adam D. DeVore

References1. "Angiotensin-neprilysin inhibition versus enalapril in heart failure". N Engl J Med . 2014;371:993-1004. 2. "Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction". N Engl J Med . 2019;381:1609-1620. 3. "Rationale, design and baseline characteristics of the PARAGLIDE-HF trial: sacubitril/valsartan vs valsartan in HFmrEF and HFpEF with a worsening heart failure event". J Card Fail . 2023;29:922-930. 4.

Jul 20, 2023 | pubmed.ncbi.nlm.nih.gov | Velazquez EJ |Yousif Ahmad |Eric Velazquez

Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software

May 22, 2023 | ahajournals.org | Stephen Greene |Eric Velazquez |Kevin J. Anstrom |Robert M. Clare

Originally publishedhttps://doi.org/10.1161/CIRCULATIONAHA.123.064842Circulation. 2023;148:124–134AbstractBackground:Loop diuretics are a primary therapy for the symptomatic treatment of heart failure (HF), but whether torsemide improves patient symptoms and quality of life better than furosemide remains unknown.